Retension Pharmaceuticals’ (NASDAQ:RTSN – Get Free Report) quiet period will end on Wednesday, November 18th. Retension Pharmaceuticals had issued 3,750,000 shares in its IPO on October 9th. The total size of the offering was $45,000,000 based on an initial share price of $12.00. During the company’s quiet period, insiders and any underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
Analysts Set New Price Targets
RTSN has been the topic of a number of research reports. Guggenheim assumed coverage on shares of Retension Pharmaceuticals in a research note on Monday, November 2nd. They issued a “buy” rating and a $55.00 price objective on the stock. Oppenheimer started coverage on shares of Retension Pharmaceuticals in a report on Tuesday, November 3rd. They set an “outperform” rating and a $50.00 target price for the company. Leerink Partners started coverage on shares of Retension Pharmaceuticals in a research report on Tuesday, November 3rd. They set a “strong-buy” rating for the company. Zacks Research began coverage on shares of Retension Pharmaceuticals in a report on Wednesday, November 4th. They issued a “hold” rating on the stock. Finally, Wall Street Zen raised Retension Pharmaceuticals to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $52.50.
Get Our Latest Stock Report on Retension Pharmaceuticals
Retension Pharmaceuticals Stock Performance
Shares of RTSN stock opened at $11.46 on Tuesday. Retension Pharmaceuticals has a twelve month low of $9.66 and a twelve month high of $18.64.
Insider Activity at Retension Pharmaceuticals
In other news, Director Franklin M. Berger bought 10,000 shares of the business’s stock in a transaction dated Tuesday, October 13th. The stock was purchased at an average cost of $12.00 per share, with a total value of $120,000.00. Following the acquisition, the director directly owned 10,000 shares in the company, valued at $120,000. This trade represents a ? increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Eric L. Keller bought 20,800 shares of the business’s stock in a transaction dated Tuesday, October 13th. The shares were purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the completion of the acquisition, the chief executive officer owned 423,377 shares in the company, valued at approximately $5,080,524. This represents a 5.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.
About Retension Pharmaceuticals
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
See Also
- Five stocks we like better than Retension Pharmaceuticals
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
